Genolution Inc. (KQ:225220) — Market Cap & Net Worth
Market Cap & Net Worth: Genolution Inc. (225220)
Genolution Inc. (KQ:225220) has a market capitalization of $15.82 Million (₩23.34 Billion) as of August 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #25788 globally and #1919 in its home market, demonstrating a -0.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genolution Inc.'s stock price ₩1292.00 by its total outstanding shares 18066570 (18.07 Million). See Genolution Inc. capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Genolution Inc. Market Cap History: 2020 to 2026
Genolution Inc.'s market capitalization history from 2020 to 2026. Data shows change from $73.74 Million to $15.82 Million (-20.88% CAGR).
Index Memberships
Genolution Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$206.59 Billion | 0.01% | #1031 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$206.59 Billion | 0.01% | #1031 of 1384 |
Weight: Genolution Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Genolution Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genolution Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Genolution Inc.'s market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $73.74 Million | $85.30 Billion | $32.05 Billion | 0.00x | 0.00x |
| 2021 | $87.36 Million | $72.83 Billion | $34.39 Billion | 0.00x | 0.00x |
| 2022 | $55.10 Million | $38.08 Billion | $14.60 Billion | 0.00x | 0.00x |
| 2023 | $46.95 Million | $9.76 Billion | -$5.55 Billion | 0.00x | N/A |
| 2024 | $27.24 Million | $7.14 Billion | -$6.83 Billion | 0.00x | N/A |
Competitor Companies of 225220 by Market Capitalization
Companies near Genolution Inc. in the global market cap rankings as of August 5, 2026.
Key companies related to Genolution Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Genolution Inc. Historical Marketcap From 2020 to 2026
Between 2020 and today, Genolution Inc.'s market cap moved from $73.74 Million to $ 15.82 Million, with a yearly change of -20.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩15.82 Million | -31.96% |
| 2025 | ₩23.25 Million | -14.65% |
| 2024 | ₩27.24 Million | -41.98% |
| 2023 | ₩46.95 Million | -14.78% |
| 2022 | ₩55.10 Million | -36.93% |
| 2021 | ₩87.36 Million | +18.47% |
| 2020 | ₩73.74 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Genolution Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.82 Million USD |
| MoneyControl | $15.82 Million USD |
| MarketWatch | $15.82 Million USD |
| marketcap.company | $15.82 Million USD |
| Reuters | $15.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genolution Inc.
Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/… Read more